What age group was studied in STEP-TEENS?

The trial enrolled adolescents aged 12 to 17 years (inclusive at randomization). The mean age was approximately 15.4 years. No participants younger than 12 were included, and the FDA approval reflects this lower age bound.

How does semaglutide weight loss in teens compare to adults?

The 16.1% BMI reduction in adolescents is comparable to the 12-15% body weight reduction seen in adult STEP trials. Direct comparison is complicated because the adolescent trial used BMI change (accounting for expected growth) rather than absolute weight change as the primary endpoint. The treatment effect relative to placebo was actually larger in teens (16.7 percentage points) than in most adult cohorts.

Does semaglutide affect growth or puberty in adolescents?

In the 68-week trial period, linear growth velocity and pubertal progression were not impaired in semaglutide-treated participants. Height gain was similar between groups. Longer-term data are needed to fully evaluate effects across the full pubertal trajectory.

What are the most common side effects of semaglutide in teens?

Gastrointestinal symptoms dominate: nausea (44%), vomiting (26%), and diarrhea (20%). Most occurred during the 16-week dose escalation period and were mild to moderate. Cholelithiasis (gallstones) occurred in 3.7% of semaglutide-treated adolescents, a rate higher than expected in untreated teenagers.

Is Wegovy FDA-approved for adolescents?

Yes. In March 2023, the FDA approved Wegovy (semaglutide 2.4 mg) for chronic weight management in patients aged 12 years and older with a BMI at the 95th percentile or greater for their age and sex. This approval was based primarily on STEP-TEENS data.

Does insurance cover semaglutide for teenagers?

Coverage is highly variable. Many commercial plans require prior authorization and documentation of failed lifestyle intervention. Multiple state Medicaid programs exclude anti-obesity medications from formularies regardless of patient age. Families should expect to work with their prescriber on appeals and documentation.

What happens when adolescents stop taking semaglutide?

The 7-week off-treatment follow-up in STEP-TEENS showed rapid partial weight regain. Roughly one-third of the BMI reduction was lost within weeks of discontinuation. This pattern is consistent with adult GLP-1 data and raises questions about optimal treatment duration, which remain unanswered.

Did STEP-TEENS include racially diverse participants?

The trial population was 72% white. Black, Hispanic, and other racial/ethnic groups were underrepresented relative to their share of adolescent obesity burden in the United States. This limits the generalizability of both efficacy and safety findings to the populations most affected by pediatric obesity.

How does the AAP guideline reflect STEP-TEENS findings?

The January 2023 AAP clinical practice guideline recommends offering pharmacotherapy to adolescents aged 12 and older with obesity, citing STEP-TEENS as key supporting evidence. This marked the first time the AAP endorsed early pharmacotherapy rather than positioning it as a last resort after prolonged behavioral intervention.

Should clinicians prescribe semaglutide to all adolescents with obesity?

No. The trial supports use in adolescents aged 12-17 with BMI at or above the 95th percentile who have attempted structured lifestyle changes. Clinicians should screen for contraindications (medullary thyroid carcinoma history, MEN2), eating disorder risk, and medication-induced obesity before prescribing. Non-response by 16-20 weeks should prompt reassessment.

What STEP-TEENS Actually Changes in Clinical Practice

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |---|---| | Trial name | STEP-TEENS (NCT04102685) | | N | 201 (semaglutide 134, placebo 67) | | Population | Adolescents aged 12-17 with obesity (BMI ≥95th percentile) or overweight (≥85th percentile) with at least one weight-related comorbidity | | Intervention | Subcutaneous semaglutide 2.4 mg once weekly | | Comparator | Matched placebo injection, both arms receiving lifestyle intervention | | Duration | 68 weeks (16-week dose escalation + 52-week maintenance) | | Primary endpoint | Percentage change in BMI from baseline at week 68 | | Key result | BMI change of -16.1% (semaglutide) vs +0.6% (placebo); estimated treatment difference -16.7 percentage points (p < 0.001) | | Publication | Weghuber et al., NEJM, December 2022 |

Why This Trial Exists

Before STEP-TEENS, the pharmacotherapy toolkit for adolescent obesity was thin. Orlistat carried an FDA indication for ages 12 and up but produced modest results (roughly 2-3% placebo-subtracted BMI reduction) with gastrointestinal side effects that limited adherence. Phentermine lacked formal pediatric approval. Bariatric surgery worked but remained inaccessible to most families due to cost, geographic barriers, and institutional reluctance to operate on teenagers. The clinical reality was that most adolescents with severe obesity received lifestyle counseling alone, and longitudinal data showed that fewer than 5% of adolescents with severe obesity achieved clinically meaningful weight reduction through behavioral intervention by itself.

Semaglutide 2.4 mg had already proven effective in the adult STEP program, producing 12-15% weight loss across multiple adult populations. STEP-TEENS asked whether those results would hold in a developing body during puberty, a period when hormonal shifts, growth velocity, and psychological vulnerability complicate both the disease and the treatment.

Methodology: What the Abstract Does Not Tell You

The STEP-TEENS trial used a 2:1 randomization favoring semaglutide, a design choice that improved statistical power for safety signal detection in a smaller pediatric population. All participants received standardized lifestyle intervention consisting of dietary counseling, physical activity guidance, and behavioral support, delivered with equal intensity across both arms.

The HealthRX Clinical Translation Framework for STEP-TEENS

When reading any pediatric obesity trial, clinicians should filter results through four questions that determine real-world applicability. We use this framework throughout our analysis:

Growth safety: Did the intervention interfere with linear growth or pubertal development?
Population match: How closely does the trial cohort resemble the patients actually presenting to your clinic?
Durability signal: What happened when the drug stopped, and what does that imply for treatment duration?
Access reality: Can the patients who need this drug actually get it?

Applying this framework to STEP-TEENS reveals both its strengths and its gaps.

Dose Escalation and Adherence

The 16-week titration schedule mirrored the adult protocol: 0.25 mg weekly for 4 weeks, then stepwise increases to 2.4 mg. 89% of participants in the semaglutide arm completed the full escalation. This is a higher completion rate than most adult GLP-1 trials report, possibly reflecting stronger parental oversight of medication adherence. The trial did not report whether participants self-injected or relied on caregivers, a detail that matters for real-world implementation.

Exclusion Criteria Worth Noting

The trial excluded adolescents with type 1 diabetes, prior bariatric surgery, or obesity secondary to endocrine disorders. It also excluded those using medications known to cause significant weight gain. In practice, many adolescents with severe obesity are taking antipsychotics, antiepileptics, or corticosteroids. The trial population was, by design, a relatively "clean" cohort. Clinicians extrapolating these results to medically complex teenagers should do so cautiously.

Results Beyond the Headline Number

The 16.1% BMI reduction is striking, but the distribution of response matters more for individual patient counseling.

Response Distribution

| Outcome threshold | Semaglutide (%) | Placebo (%) | |---|---|---| | ≥5% BMI reduction | 72.5 | 17.7 | | ≥10% BMI reduction | 62.3 | 8.1 | | ≥15% BMI reduction | 36.6 | 3.2 | | ≥20% BMI reduction | 18.8 | 0.0 |

These data, drawn from the primary publication, show that roughly one in four semaglutide-treated adolescents did not reach even 5% BMI reduction. That is not a failure of the drug. It reflects the heterogeneity of adolescent obesity pathophysiology. The clinical message: semaglutide will not work equally well for every teenager, and non-response at 16-20 weeks should prompt reassessment rather than indefinite continuation.

Cardiometabolic Secondary Outcomes

Semaglutide improved waist circumference (estimated treatment difference: -8.1 cm), fasting insulin, and HbA1c. Lipid improvements were modest. Blood pressure reductions were not statistically significant, though the trial was not powered to detect them. These secondary findings matter because adolescent obesity is not just a weight problem. It is a metabolic trajectory problem, and even partial correction of insulin resistance during adolescence may alter the long-term cardiometabolic arc.

Safety Profile in a Growing Population

Gastrointestinal adverse events occurred in 62% of semaglutide-treated participants versus 42% on placebo. Nausea (44% vs 18%), vomiting (26% vs 9%), and diarrhea (20% vs 12%) were the most common. Most events were mild to moderate and occurred during dose escalation.

Returning to our framework's first question on growth safety: the trial reported that linear growth was not impaired over 68 weeks. Height velocity remained within normal ranges for both groups. Tanner staging progression appeared unaffected, though the trial duration was too short to draw definitive conclusions about pubertal development. This is the single most important safety finding for pediatric prescribers, and it requires longer follow-up to fully validate.

Five participants in the semaglutide group (3.7%) reported cholelithiasis. This rate exceeds what is typically seen in untreated adolescent populations and aligns with the known gallstone risk associated with rapid weight loss in any age group. Clinicians should counsel families about gallbladder symptoms, particularly when weight loss exceeds 1.5 kg per week during the early treatment phase.

What Actually Changed After Publication

FDA Approval and Label Expansion

In March 2023, the FDA expanded the Wegovy label to include adolescents aged 12 and older with an initial BMI at the 95th percentile or greater for age and sex. This made semaglutide 2.4 mg the first GLP-1 receptor agonist approved for pediatric weight management. The approval was based almost entirely on STEP-TEENS data.

Guideline Shifts

The American Academy of Pediatrics (AAP) released its first comprehensive clinical practice guideline for pediatric obesity in January 2023, recommending that clinicians offer pharmacotherapy to adolescents aged 12 and older with obesity. This was a seismic shift. Prior AAP guidance had positioned pharmacotherapy as a distant option after prolonged behavioral intervention. The AAP guideline explicitly cited STEP-TEENS as evidence supporting early pharmacotherapy.

The Endocrine Society and the Pediatric Endocrine Society both updated their positions to reflect the availability of semaglutide for adolescents, though neither issued formal standalone guidelines in direct response to the trial.

Prescribing Pattern Reality

Despite guideline updates, real-world prescribing has been slower than the evidence warrants. Insurance coverage for pediatric Wegovy remains inconsistent. Many state Medicaid programs exclude anti-obesity medications entirely, regardless of age. Prior authorization requirements frequently delay treatment initiation by weeks to months. A 2024 analysis in Pediatrics found that fewer than 8% of eligible adolescents with severe obesity had received a GLP-1 prescription within 12 months of the AAP guideline release.

This gap between evidence and access is the defining clinical implication of STEP-TEENS. The trial proved efficacy. The system has not yet delivered on that proof.

Limitations the Authors Acknowledged (and Some They Did Not)

The published limitations section notes the modest sample size (N=201), the 68-week duration, and the predominantly white and female study population (62% female, 72% white). These are real constraints. But several additional limitations deserve attention.

Weight regain after discontinuation. The 7-week off-treatment follow-up period showed rapid BMI regain in the semaglutide group. By week 75, roughly one-third of the treatment effect had been lost. This pattern mirrors adult STEP data and raises difficult questions about treatment duration. Are we committing 12-year-olds to years or decades of weekly injections? The trial does not answer this. Open-label extension data, when published, will be essential.

Psychological outcomes. The trial measured quality of life using the IWQOL-Kids instrument and found improvement in the semaglutide group. But it did not systematically assess eating disorder risk, body image disturbance, or the psychological impact of medicalized weight management during adolescence. Given that eating disorder prevalence peaks during adolescence, this omission is notable. Post-marketing surveillance and real-world studies must fill this gap.

Racial and socioeconomic diversity. The trial enrolled participants across 5 countries and 45 sites but still produced a cohort that does not reflect the populations most burdened by adolescent obesity in the United States, where Black, Hispanic, and low-income adolescents carry disproportionate obesity prevalence. Efficacy and safety in these populations cannot simply be assumed from the trial data.

Who Benefits Most (and Who Needs More Data)

Based on trial inclusion criteria and subgroup analyses, the strongest evidence supports semaglutide use in adolescents aged 12-17 who have:

BMI ≥95th percentile with or without comorbidities
Failed structured lifestyle intervention over at least 3-6 months
No contraindications (personal or family history of medullary thyroid carcinoma, MEN2 syndrome)
Access to ongoing follow-up for monitoring growth, GI symptoms, and gallbladder complications

Populations needing more data before routine prescribing include adolescents younger than 12, those with obesity secondary to medications or endocrine conditions, and those with active eating disorders or significant psychiatric comorbidity.

The Bottom Line for Prescribers

STEP-TEENS did not just show that semaglutide works in teenagers. It forced a reclassification of how pediatric medicine thinks about obesity treatment. The trial's contribution is not the 16.1% number. It is the permission structure: evidence strong enough to support pharmacotherapy as a standard clinical option, not an act of desperation, for adolescents with obesity. The remaining challenge is entirely structural. Insurance coverage, medication cost, specialist access, and long-term safety monitoring are the barriers now, not evidence.

Frequently asked questions

›

References

Weghuber D, Barrett T, Engberg S, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245-2257. PubMed
Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. PubMed
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PubMed
Wegovy (semaglutide) prescribing information. Novo Nordisk. Revised 2023. FDA Label
Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117-2128. PubMed